All patients with de novo BCR::ABL1+AML received induction chemotherapy mainly with daunorubicin (60–90 mg/m2, 3 days) and cytarabine (100–200 mg/m2, 7 days) (Table 2). Here, ABL1 is linked to acute myeloid leukemia.